ArticleNature medicine2013
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.
Andrew J Souers et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
1,657 papers cite itlatest 60 shown
this paperpooled ittrialcites it